Date: 05 Oct 2010
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The phosphatidyl inositol 3-kinase (PI3K)/Akt pathway mediates the effects of a variety of extracellular signals in a number of cellular processes including cell growth, proliferation, and survival. The alteration of integrants of this pathway through mutation of its coding genes increases the activation status of the signaling and can thus lead to cellular transformation. The frequent dysregulation of the PI3K/Akt pathway in breast cancer (BC) and the mediation of this pathway in different processes characteristically implicated in tumorigenesis have attracted the interest of this pathway in BC; however, a more comprehensive understanding of the signaling intricacies is necessary to develop clinical applications of the modulation of this pathway in this pathology. We review a series of experiments examining the contribution of alteration of integrants of this signaling network to human BC and we make an update of the information about the effect of the modulation of this pathway in this cancer.
Chalhoub, N., & Baker, S. J. (2009). PTEN and the PI3-kinase pathway in cancer. Annual Review of Patholology, 4, 127–150.CrossRef
Yilmaz, M., & Christofori, G. (2009). EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Reviews, 28(1–2), 15–33.PubMed
S. Loi, B.H.-K., F. Lallemand, L. Pusztai, A. Bardelli, C. Gillett, P. Ellis, M. J. Piccart-Gebhart, W. A. Phillips, G. A. McArthur, C. Sotiriou (2009) Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER + breast cancers. In ASCO. Journal of Clinical Oncology 27:15s (suppl; abstr 533)
Lopez-Knowles, E., et al. (2010). PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. International Journal of Cancer, 126(5), 1121–1131.
Park, S. S., & Kim, S. W. (2007). Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Oncology Reports, 18(1), 139–143.PubMed
Tokunaga, E., et al. (2006). Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. International Journal of Cancer, 118(2), 284–289.CrossRef
Mottolese M, N.F., Di Benedetto A, Melucci E, Sperduti I, Perracchio L, Buglioni S, Vici P, Nisticò C, Pinnarò P, Fabi A, Bria E Regina Elena (2009) Identification of an Adverse Biologic Profile in Cyclophosphamide/Metotrexate/5-Fluorouracil Treated Early Stage Breast Cancer Patients by Immunohistochemical Analysis of PI3K/p-Akt Pathway Alterations. In San Antonio Breast Cancer Meeting.
Sakr R, C.S., Wynveen C, Barbashina V, Arroyo C, Morrogh M, Heguy A, Olvera N, Rosen N, Morrow M, King T (2009) Reduced/Absent PTEN Expression Is More Common in HER2 Non-Amplified DCIS. In San Antonio Breast Cancer Meeting
Dupont J, L.A., Knoop A, Ewertz M, Barrett CJ, Hackl W, Bandaru R, Crowell T, Rheinhardt J, Liu W, Gardner H (2009) PIK3CA Mutations Can Be Acquired during Tumor Progression in Breast Cancer. In San Antonio Breast Cancer Meeting
Bachman, K. E., et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biology & Therapy, 3(8), 772–775.CrossRef
Bozhanov, S.S., et al (2010) Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. Journal of Cancer Research and Clinical Oncology, 136(11), 1657–1669.
Perren, A., et al. (1999). Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. American Journal of Pathology, 155(4), 1253–1260.PubMed
Lee, J. S., et al. (2004). Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast. Applied Immunohistochemistry & Molecular Morphology, 12(3), 205–210.CrossRef
Zhu, L., Loo, W. T., & Louis, W. C. (2007). PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer. Biomedicine & Pharmacotherapy, 61(9), 558–561.CrossRef
Yamnik, R. L., & Holz, M. K. (2009). mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Letters, 584(1), 124–128.CrossRef
Miller TW, F.E., Gonzalez-Angulo AM, Hennessy BT, Mills GB, McKinley ET, Manning HC, Arteaga CL (2009) Resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer is dependent upon phosphatidylinositol-3 kinase (PI3K) signaling. In San Antonio Breast Cancer Meeting
She, S. C., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., et al. (2009). Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. Cancer Research, 69, 3061.
Speicher TJ, H.W., Lipton A. (2009) Synergistic Growth Inhibition with a PI3 Kinase/mTOR Inhibitor Plus Lapatinib. In San Antonio Breast Cancer Meeting.
Vorkas PA, A.S., Poumpouridou N, Kroupis C, Mavroudis D, Stathopoulos E, Georgoulias V, Lianidou ES (2009) PI3K Pathway Activity and Response to First-Line Chemotherapy in Combination with Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer. In San Antonio Breast Cancer Meeting.
Carracedo, A., et al. (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation, 118(9), 3065–3074.PubMed
Sharon Barr, S.R., Elizabeth Buck, David Epstein, Mark Miglarese (2010) Co-targeting mTOR and IGF-1R/IR results in synergistic activity against a broad array of tumor cell lines, independent of KRAS mutation status. In AACR 101st Annual Meeting.
F. Janku, A.M.T., I. Garrido- Laguna, D. S. Hong, A. Naing, G. S. Falchook, J. J. Wheler, S. Fu, S. A. Piha-Paul, R. Kurzrock (2010) PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. In ASCO 2010 Meeting. Chicago: Journal of Clinical Oncology
H. Burris, J.R., S. Sharma, R. S. Herbst, J. Tabernero, J. R. Infante, A. Silva, D. Demanse, W. Hackl, J. Baselga (2010) First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. In ASCO 2010 Meeting. Journal of Clinical Oncology
D. Sarker, R.K., K. E. Mazina, J. A. Ware, Y. Yan, M. Dresser, M. K. Derynck and J. De-Bono (2009) A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. In ASCO. Journal of Clinical Oncology
J. Baselga, M.J.D.J., J. Rodon, H. A. Burris III, D. C. Birle, S. S. De Buck, D. Demanse, Q. C. Ru, M. Goldbrunner, J. C. Bendell (2010) A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. In ASCO 2010 Meeting. Journal of Clinical Oncology
Chow LWC, S.Y., Jassem J, Baselga J, Hayes DF, Wolff AC, Hachemi S, Cincotta M, Yu BW, Kong S, Moore L (2006) Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. In San Antonio Breast Cancer Meeting. Breast Cancer Research and Treatment
Chen CS, C.M., Imaoka RT, Svahn T, Guardino AE (2009) A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination with Capecitabine for Metastatic Breast Cancer. In San Antonio Breast Cancer Meeting.
Cardoso F, D.V., Campone M, Massacesi C, Manlius C, Thevenaz P, Zhang Y, Jerusalem G, Sahmoud T, Andre F, Gianni L (2009) Everolimus (Afinitor®), Trastuzumab (H), and Paclitaxel (P) or Vinorelbine (V) in the Treatment of HER-2+ Metastatic Breast Cancer (MBC) Patients (Pts) Pre-Treated with Lapatinib-Containing Therapy: Pooled Analysis of 2 Phase I Studies. In San Antonio Breast Cancer Meeting.
G. H. Jerusalem, V.D., F. Cardoso, J. Bergh, A. Fasolo, A. Rorive, C. Manlius, I. Pylvaenaeinen, T. Sahmoud, L. Gianni (2008) Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. In ASCO Annual Meeting. Journal of Clinical Oncology
M. Campone, R.O.R., S. Hurvitz, M. Naughton, C. Manlius, L. Vittori, P. Mukhopadhyay, C. Massacesi, T. Sahmoud, F. André (2009) Everolimus plus weekly paclitaxel and trastuzumab in patients (pts) with HER-2+ metastatic breast cancer (MBC) with prior resistance to trastuzumab: a phase I clinical trial. In San Antonio Breast Cancer Meeting.
P. H. Morrow, G.M.W., D. J. Booser, J. A. Moore, P. R. Flores, I. E. Krop, E. P. Winer, G. N. Hortobagyi, D. Yu, F. J. Esteva (2010) Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. In ASCO 2010 Meeting. Journal of Clinical Oncology
F. Dalenc, M.C., P. Hupperets, R. O’Regan, C. Manlius, L. Vittori, P. Mukhopadhyay, C. Massacesi, T. Sahmoud, F. Andre (2010) Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial. In ASCO 2010 Meeting. Journal of Clinical Oncology
D. Yardley, M.S., I. Ray-Coquard, B. Melichar, L. Hart, V. Dieras, M. Barve, A. Melnyk, A. Richard, D. Dorer, C. Turner, P. Dodion (2009) Ridaforolimus (AP23573; MK-8669) in combination with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer: a multicenter phase 2 clinical trial. In San Antonio Breast Cancer Meeting.
- The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
Cancer and Metastasis Reviews
Volume 29, Issue 4 , pp 751-759
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- breast cancer
- Industry Sectors